Journal article
Desloratadine for allergic rhinitis
Abstract
Seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) affect up to 40% of the population (depending on geographical area), and are associated with significant morbidity, socioeconomic costs and reductions in quality of life. Antihistamines are a first-line therapy, with newer nonsedating agents having superseded sedating first-generation drugs. Desloratadine is a nonsedating, nonimpairing antihistamine that is effective in …
Authors
Wilken JA; Daly AF; Sullivan CL; Kim H
Journal
Expert Review of Clinical Immunology, Vol. 2, No. 2, pp. 209–224
Publisher
Taylor & Francis
Publication Date
March 2006
DOI
10.1586/1744666x.2.2.209
ISSN
1744-666X